Literature DB >> 10423672

Primary aldosteronism: A common and curable form of hypertension.

W F Young1.   

Abstract

Since its initial description in 1955, primary aldosteronism was thought to be a rare cause of hypertension. However, with improved screening methodologies, it appears that primary aldosteronism is the most common form of secondary hypertension. Diagnosis of this disorder results in either the cure of hypertension or targeted pharmacotherapy. In addition, recent evidence suggests that aldosterone excess may have specific cardiotoxicity that is reversible with treatment. Patients with hypertension and hypokalemia and most patients with treatment-resistant hypertension should undergo screening for primary aldosteronism. A random and ambulatory ratio of plasma aldosterone concentration (ng/dl) to plasma renin activity (ng/ml per hour) >20 and a plasma aldosterone concentration >15 ng/dl is a positive screen for primary aldosteronism. A plasma aldosterone concentration/plasma renin activity ratio >20 alone is not diagnostic of primary aldosteronism; primary aldosteronism must be confirmed by demonstrating inappropriate aldosterone secretion with either the intravenous saline suppression test or measurement of 24-hour urinary aldosterone while on a high-sodium diet. The 2 major subtypes of primary aldosteronism are unilateral aldosterone-producing adenoma and bilateral idiopathic hyperplasia. Patients with aldosterone-producing adenoma are usually treated with unilateral adrenalectomy, and patients with idiopathic hyperplasia are treated medically. The subtype evaluation may require one or more tests, the first of which is imaging the adrenals with computed tomography (CT). When CT reveals a solitary unilateral macroadenoma (>1 centimeter) and normal contralateral adrenal morphology in a patient with primary aldosteronism, unilateral laparoscopic adrenalectomy is a reasonable therapeutic option. However, in many cases, CT imaging may reveal normal-appearing adrenals or ambiguous findings. Adrenal venous sampling helps solve these clinical dilemmas.

Entities:  

Mesh:

Year:  1999        PMID: 10423672

Source DB:  PubMed          Journal:  Cardiol Rev        ISSN: 1061-5377            Impact factor:   2.644


  20 in total

1.  The renal thiazide-sensitive Na-Cl cotransporter as mediator of the aldosterone-escape phenomenon.

Authors:  X Y Wang; S Masilamani; J Nielsen; T H Kwon; H L Brooks; S Nielsen; M A Knepper
Journal:  J Clin Invest       Date:  2001-07       Impact factor: 14.808

Review 2.  Primary aldosteronism: rare bird or common cause of secondary hypertension?

Authors:  M Stowasser
Journal:  Curr Hypertens Rep       Date:  2001-06       Impact factor: 5.369

3.  Laboratory investigation of primary aldosteronism.

Authors:  Michael Stowasser; Paul J Taylor; Eduardo Pimenta; Ashraf H Al-Asaly Ahmed; Richard D Gordon
Journal:  Clin Biochem Rev       Date:  2010-05

Review 4.  Treatment of resistant hypertension.

Authors:  Sandra J Taler
Journal:  Curr Hypertens Rep       Date:  2005-10       Impact factor: 5.369

Review 5.  Minimal access adrenal surgery.

Authors:  L M Brunt
Journal:  Surg Endosc       Date:  2006-01-25       Impact factor: 4.584

6.  Cortex sparing laparoscopic adrenalectomy in a patient with Conn's syndrome.

Authors:  Fahri Yetişir; A Ebru Salman; Alper Özkardeş; Mehmet Tokaç; Burak Çiftçi; Mehmet Kılıç
Journal:  Ulus Cerrahi Derg       Date:  2013-03-01

7.  Outcome of surgery for primary hyperaldosteronism.

Authors:  Jens Waldmann; Lisa Maurer; Julia Holler; Peter H Kann; Annette Ramaswamy; Detlef K Bartsch; Peter Langer
Journal:  World J Surg       Date:  2011-11       Impact factor: 3.352

8.  Noninvasive adrenal imaging in hyperaldosteronism: is it accurate for correctly identifying patients who should be selected for surgery?

Authors:  Celestino Pio Lombardi; Marco Raffaelli; Carmela De Crea; Vittoria Rufini; Giorgio Treglia; Rocco Bellantone
Journal:  Langenbecks Arch Surg       Date:  2007-01-23       Impact factor: 3.445

Review 9.  Functional tests for primary aldosteronism: value of captopril suppression.

Authors:  Marie-Claude Racine; Pierre Douville; Marcel Lebel
Journal:  Curr Hypertens Rep       Date:  2002-06       Impact factor: 5.369

10.  Predictors of resolution of hypertension after adrenalectomy in patients with aldosterone-producing adenoma.

Authors:  Ra Mi Kim; Jandee Lee; Euy-Young Soh
Journal:  J Korean Med Sci       Date:  2010-06-17       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.